CINGULATE INC. CING 深 滬
已收盤 10-10 16:00:00 美东时间
4.11
-0.240
-5.52%
華盛通- 最 高4.40
- 今 開4.34
- 成交量 17.57万股
- 最 低 4.03
- 昨 收 4.35
- 總市值 2304.07万
- 52周最高 6.01
- 市盈率 靜 --
- 換手率 3.13%
- 52周最低 3.02
- 委 比 48.98%
- 總股本 560.60万
- 歷史最高 1236.00
- 量 比 1.15
- 振 幅 8.51%
- 歷史最低 2.574
- 每 手 1
- 風險率 0.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Battery Tech Company Solidion Restructures $4M Financing to Boost Shareholder Value
Solidion Technology Inc. ("Solidion" or the "Company") (NASDAQ:STI), an advanced battery technology solutions provider, announces a comprehensive restructuring of its previous $4 million equity financing announced on
10-08 18:08
CONTANGO PROVIDES UPDATE ON FINANACING AND EXPLORATION PLANS
FAIRBANKS, Alaska, Sept. 26, 2025 /PRNewswire/ - Contango ORE, Inc. ("Contango" or the "Company") (NYSE American: CTGO), announces that it will hold a webinar on Friday, September 26, 2025 a...
09-26 22:07
Cingulate Inc Approves Stock Issuance Proposal
Cingulate Inc ( ($CING) ) has shared an update. On September 25, 2025, Cingulat...
09-26 05:30
CROWN HOLDINGS, INC. ANNOUNCES PRICING OF SENIOR NOTES
TAMPA, Fla., Sept. 22, 2025 /PRNewswire/ -- Crown Holdings, Inc. (NYSE: CCK) announced today that it has priced an offering of €500 million aggregate principal amount of 3.750% senior unsecu...
09-23 04:05
Cingulate Enters Commercial Supply Agreement With Bend Bio Sciences For Manufacturing Of CTx-1301, Its Lead Drug Candidate For Treating ADHD
Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation
09-17 20:55
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
Cingulate Inc. entered into a commercial supply agreement with Bend Bio Sciences for the manufacturing of CTx-1301, an extended-release tablet for ADHD treatment. Cingulate submitted an NDA for CTx-1301 to the FDA on July 31, 2025. The agreement ensures manufacturing security and operational efficiency as Cingulate prepares for potential market entry. bend's expertise in modified-release dosage forms aligns with Cingulate's PTR drug delivery plat...
09-17 12:45
Cingulate Inc Manages Debt with Stock Issuances
Cingulate Inc ( ($CING) ) just unveiled an announcement. Between July 22, 2025,...
09-06 05:33
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights
Extensive strategic, financial and operational overhaul has reshaped and refocused our business; Strong progress on multiple fronts Commercial and R&D Highlights: Recruitment initiated in th...
09-05 19:00
Cingulate Inc Appoints New Executive Chairman Amid Changes
Cingulate Inc ( ($CING) ) has issued an announcement. On August 14, 2025, Cingu...
08-29 05:48
Ascendiant Capital Maintains Buy on Cingulate, Raises Price Target to $62
Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and raises the price target from $61 to $62.
08-22 17:54
